Damien Leveque , Soufiane Lebal , Tristan Goudou , Mihaela Giol , Denis Debrosse , Marielle LE Roux , Thérésa Khalife-Hocquemiller , Anna Vayssette , Juliette Camuset , Alexandra Rousseau , Jalal Assouad , Harry Etienne
{"title":"节段切除适应症是否应扩展到小于3cm且未累及淋巴结的非小细胞肺癌?回顾性单中心研究","authors":"Damien Leveque , Soufiane Lebal , Tristan Goudou , Mihaela Giol , Denis Debrosse , Marielle LE Roux , Thérésa Khalife-Hocquemiller , Anna Vayssette , Juliette Camuset , Alexandra Rousseau , Jalal Assouad , Harry Etienne","doi":"10.1016/j.resmer.2025.101179","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Surgical resection remains the standard treatment for stage IA non-small cell lung cancers (NSCLC). The dual objective of this study is to compare long-term outcomes of lobectomies and segmentectomies for stage IA NSCLC and to identify prognostic factors for resected stage IA NSCLC.</div></div><div><h3>Materials and Methods</h3><div>This is a retrospective monocentric study including patients diagnosed with NSCLC smaller than 3 cm, without lymph node involvement, from November 2015 to November 2021. The primary endpoint was event-free survival (EFS), defined as time from surgery to recurrence or all-cause death. Secondary endpoints included overall survival, recurrence-free survival, and short-term postoperative outcomes (length of stay, drainage duration, 30-day mortality, and postoperative complications). Prognostic factors were analyzed using multivariate Cox regression adjusted for variables identified in univariate analysis.</div></div><div><h3>Results</h3><div>A total of 457 patients underwent surgery for stage cIA NSCLC during the 11study period. Of these, 176 (38.5 %) had a segmentectomy, and 281 (61.5 %) underwent lobectomy. Among patients with cT1N0 tumors, the 5-year event-free survival did not significantly differ between the segmentectomy and lobectomy groups (adjusted HR = 0.59 (0.32; 1.08), <em>p</em> = 0.086), with 5-year event-free rates of 75.0 % and 83.0 %, respectively (<em>p</em> = 0.054). Multivariate analysis revealed an association between nodule type (solid vs. ground-glass or mixed) and event-free survival (death and/or recurrence) ([adjusted HR =2.07 (1.17–3.66), <em>p</em> = 0.01)]. Vascular and/or lymphatic invasion is associated with a decrease in event-free survival (recurrence or death) [adjusted HR = 2.25 (1.29; 3.92), <em>p</em> = 0.004]. Conversion from segmentectomy to lobectomy occurred in 6 patients (3.4 %), and they were included in the lobectomy group for analysis.</div></div><div><h3>Conclusion</h3><div>For patients with clinical stage cIA NSCLC, segmentectomy appears to offer comparable oncologic outcomes to lobectomy. Tumor characteristics, including radiological appearance and histological factors, should be carefully considered when selecting the appropriate surgical strategy. Prospective multicenter studies are needed to confirm these findings.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101179"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should segmentectomy indications be extended to NSCLC smaller than 3 cm without lymph node involvement? A retrospective single-center study\",\"authors\":\"Damien Leveque , Soufiane Lebal , Tristan Goudou , Mihaela Giol , Denis Debrosse , Marielle LE Roux , Thérésa Khalife-Hocquemiller , Anna Vayssette , Juliette Camuset , Alexandra Rousseau , Jalal Assouad , Harry Etienne\",\"doi\":\"10.1016/j.resmer.2025.101179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Surgical resection remains the standard treatment for stage IA non-small cell lung cancers (NSCLC). The dual objective of this study is to compare long-term outcomes of lobectomies and segmentectomies for stage IA NSCLC and to identify prognostic factors for resected stage IA NSCLC.</div></div><div><h3>Materials and Methods</h3><div>This is a retrospective monocentric study including patients diagnosed with NSCLC smaller than 3 cm, without lymph node involvement, from November 2015 to November 2021. The primary endpoint was event-free survival (EFS), defined as time from surgery to recurrence or all-cause death. Secondary endpoints included overall survival, recurrence-free survival, and short-term postoperative outcomes (length of stay, drainage duration, 30-day mortality, and postoperative complications). Prognostic factors were analyzed using multivariate Cox regression adjusted for variables identified in univariate analysis.</div></div><div><h3>Results</h3><div>A total of 457 patients underwent surgery for stage cIA NSCLC during the 11study period. Of these, 176 (38.5 %) had a segmentectomy, and 281 (61.5 %) underwent lobectomy. Among patients with cT1N0 tumors, the 5-year event-free survival did not significantly differ between the segmentectomy and lobectomy groups (adjusted HR = 0.59 (0.32; 1.08), <em>p</em> = 0.086), with 5-year event-free rates of 75.0 % and 83.0 %, respectively (<em>p</em> = 0.054). Multivariate analysis revealed an association between nodule type (solid vs. ground-glass or mixed) and event-free survival (death and/or recurrence) ([adjusted HR =2.07 (1.17–3.66), <em>p</em> = 0.01)]. Vascular and/or lymphatic invasion is associated with a decrease in event-free survival (recurrence or death) [adjusted HR = 2.25 (1.29; 3.92), <em>p</em> = 0.004]. Conversion from segmentectomy to lobectomy occurred in 6 patients (3.4 %), and they were included in the lobectomy group for analysis.</div></div><div><h3>Conclusion</h3><div>For patients with clinical stage cIA NSCLC, segmentectomy appears to offer comparable oncologic outcomes to lobectomy. Tumor characteristics, including radiological appearance and histological factors, should be carefully considered when selecting the appropriate surgical strategy. Prospective multicenter studies are needed to confirm these findings.</div></div>\",\"PeriodicalId\":48479,\"journal\":{\"name\":\"Respiratory Medicine and Research\",\"volume\":\"88 \",\"pages\":\"Article 101179\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590041225000261\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine and Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590041225000261","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
手术切除仍然是IA期非小细胞肺癌(NSCLC)的标准治疗方法。本研究的双重目的是比较IA期非小细胞肺癌肺叶切除术和节段切除术的长期预后,并确定切除的IA期非小细胞肺癌的预后因素。材料和方法这是一项回顾性单中心研究,包括2015年11月至2021年11月诊断为小于3cm的非小细胞肺癌,无淋巴结累及的患者。主要终点为无事件生存期(EFS),定义为从手术到复发或全因死亡的时间。次要终点包括总生存期、无复发生存期和短期术后结局(住院时间、引流时间、30天死亡率和术后并发症)。预后因素采用多因素Cox回归分析,对单因素分析中确定的变量进行校正。结果在11个研究期间,共有457例患者接受了cIA期NSCLC手术治疗。其中,176例(38.5%)行节段切除术,281例(61.5%)行肺叶切除术。在cT1N0肿瘤患者中,节段切除术组和肺叶切除术组的5年无事件生存率无显著差异(调整后HR = 0.59 (0.32;1.08), p = 0.086), 5年无事件率分别为75.0%和83.0% (p = 0.054)。多因素分析显示,结节类型(实性、磨玻璃性或混合性)与无事件生存率(死亡和/或复发)之间存在相关性(调整后风险比=2.07 (1.17-3.66),p = 0.01)。血管和/或淋巴浸润与无事件生存率(复发或死亡)降低相关[调整后风险比= 2.25 (1.29;3.92), p = 0.004]。从节段切除术转为肺叶切除术的患者有6例(3.4%),并纳入肺叶切除术组进行分析。结论对于临床分期为cIA期的非小细胞肺癌患者,节段切除术似乎与肺叶切除术具有相当的肿瘤预后。在选择合适的手术策略时,应仔细考虑肿瘤的特征,包括影像学表现和组织学因素。需要前瞻性多中心研究来证实这些发现。
Should segmentectomy indications be extended to NSCLC smaller than 3 cm without lymph node involvement? A retrospective single-center study
Introduction
Surgical resection remains the standard treatment for stage IA non-small cell lung cancers (NSCLC). The dual objective of this study is to compare long-term outcomes of lobectomies and segmentectomies for stage IA NSCLC and to identify prognostic factors for resected stage IA NSCLC.
Materials and Methods
This is a retrospective monocentric study including patients diagnosed with NSCLC smaller than 3 cm, without lymph node involvement, from November 2015 to November 2021. The primary endpoint was event-free survival (EFS), defined as time from surgery to recurrence or all-cause death. Secondary endpoints included overall survival, recurrence-free survival, and short-term postoperative outcomes (length of stay, drainage duration, 30-day mortality, and postoperative complications). Prognostic factors were analyzed using multivariate Cox regression adjusted for variables identified in univariate analysis.
Results
A total of 457 patients underwent surgery for stage cIA NSCLC during the 11study period. Of these, 176 (38.5 %) had a segmentectomy, and 281 (61.5 %) underwent lobectomy. Among patients with cT1N0 tumors, the 5-year event-free survival did not significantly differ between the segmentectomy and lobectomy groups (adjusted HR = 0.59 (0.32; 1.08), p = 0.086), with 5-year event-free rates of 75.0 % and 83.0 %, respectively (p = 0.054). Multivariate analysis revealed an association between nodule type (solid vs. ground-glass or mixed) and event-free survival (death and/or recurrence) ([adjusted HR =2.07 (1.17–3.66), p = 0.01)]. Vascular and/or lymphatic invasion is associated with a decrease in event-free survival (recurrence or death) [adjusted HR = 2.25 (1.29; 3.92), p = 0.004]. Conversion from segmentectomy to lobectomy occurred in 6 patients (3.4 %), and they were included in the lobectomy group for analysis.
Conclusion
For patients with clinical stage cIA NSCLC, segmentectomy appears to offer comparable oncologic outcomes to lobectomy. Tumor characteristics, including radiological appearance and histological factors, should be carefully considered when selecting the appropriate surgical strategy. Prospective multicenter studies are needed to confirm these findings.